Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2005 1
2006 12
2007 12
2008 16
2009 8
2010 9
2011 8
2012 8
2013 10
2014 12
2015 5
2016 3
2017 8
2018 9
2019 9
2020 6
2021 10
2022 5
2023 7
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

148 results

Results by year

Filters applied: . Clear all
Page 1
Retapamulin.
[No authors listed] [No authors listed] 2023 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2023 Apr 15. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30000967 Free Books & Documents. Review.
No information is available on the use of retapamulin during breastfeeding. Because retapamulin is poorly absorbed after topical application, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants after maternal app …
No information is available on the use of retapamulin during breastfeeding. Because retapamulin is poorly absorbed after topic …
Retapamulin.
[No authors listed] [No authors listed] Aust Prescr. 2015 Feb;38(1):33-4. doi: 10.18773/austprescr.2015.013. Epub 2014 Nov 6. Aust Prescr. 2015. PMID: 26648610 Free PMC article. Review. No abstract available.
Retapamulin: a new topical antibiotic for the treatment of uncomplicated skin infections.
Parish LC, Parish JL. Parish LC, et al. Drugs Today (Barc). 2008 Feb;44(2):91-102. doi: 10.1358/dot.2008.44.2.1153446. Drugs Today (Barc). 2008. PMID: 18389088 Review.
Retapamulin acts as a potent inhibitor of bacterial protein synthesis and has a unique mode of antibiotic action. ...Retapamulin was also clinically effective against isolates resistant to existing therapies. ...
Retapamulin acts as a potent inhibitor of bacterial protein synthesis and has a unique mode of antibiotic action. ...Retapamulin …
Retapamulin: a review of its use in the management of impetigo and other uncomplicated superficial skin infections.
Yang LP, Keam SJ. Yang LP, et al. Drugs. 2008;68(6):855-73. doi: 10.2165/00003495-200868060-00008. Drugs. 2008. PMID: 18416589 Review.
Retapamulin has a novel site of action on bacterial ribosomes. In clinical trials in patients with impetigo, topical retapamulin 1% ointment twice daily for 5 days (the approved regimen) was superior to placebo; treatment with retapamulin was noninferior to t …
Retapamulin has a novel site of action on bacterial ribosomes. In clinical trials in patients with impetigo, topical retapamulin …
Retapamulin Activity Against Pediatric Strains of Mupirocin-resistant Methicillin-resistant Staphylococcus aureus.
Patel AB, Lighter J, Fulmer Y, Copin R, Ratner AJ, Shopsin B. Patel AB, et al. Pediatr Infect Dis J. 2021 Jul 1;40(7):637-638. doi: 10.1097/INF.0000000000003123. Pediatr Infect Dis J. 2021. PMID: 33657598 Free PMC article.
All strains were susceptible to retapamulin with minimum inhibitory concentrations 0.5 mug/mL. DNA sequence analysis of rplC and cfr identified one rplC strain variant that did not demonstrate reduced phenotypic susceptibility to retapamulin. These results demonstra …
All strains were susceptible to retapamulin with minimum inhibitory concentrations 0.5 mug/mL. DNA sequence analysis of rplC and cfr …
Impetigo: diagnosis and treatment.
Hartman-Adams H, Banvard C, Juckett G. Hartman-Adams H, et al. Am Fam Physician. 2014 Aug 15;90(4):229-35. Am Fam Physician. 2014. PMID: 25250996 Free article. Review.
Treatment includes topical antibiotics such as mupirocin, retapamulin, and fusidic acid. Oral antibiotic therapy can be used for impetigo with large bullae or when topical therapy is impractical. ...Empiric treatment considerations have changed with the increasing prevalen …
Treatment includes topical antibiotics such as mupirocin, retapamulin, and fusidic acid. Oral antibiotic therapy can be used for impe …
Molecule of the month. Retapamulin.
[No authors listed] [No authors listed] Drug News Perspect. 2006 Dec;19(10):636. Drug News Perspect. 2006. PMID: 17299606 Review. No abstract available.
Microbiological profile of a new topical antibacterial: retapamulin ointment 1%.
Scangarella-Oman NE, Shawar RM, Bouchillon S, Hoban D. Scangarella-Oman NE, et al. Expert Rev Anti Infect Ther. 2009 Apr;7(3):269-79. doi: 10.1586/eri.09.7. Expert Rev Anti Infect Ther. 2009. PMID: 19344241 Review.
Retapamulin is a new topical pleuromutilin antibiotic for the treatment of skin and skin-structure infections, including impetigo. ...Topical retapamulin has a good safety profile and is associated with high patient compliance....
Retapamulin is a new topical pleuromutilin antibiotic for the treatment of skin and skin-structure infections, including impetigo. .. …
Retapamulin: what is the role of this topical antimicrobial in the treatment of bacterial infections in atopic dermatitis?
Moody MN, Morrison LK, Tyring SK. Moody MN, et al. Skin Therapy Lett. 2010 Jan;15(1):1-4. Skin Therapy Lett. 2010. PMID: 20066388 Free article. Review.
Clinical studies exploring the treatment of secondarily infected dermatitis reveal that the efficacy of topical retapamulin is comparable to a 10-day course of oral cephalexin or to topical fusidic acid. Retapamulin appears to be a much needed antimicrobial option f …
Clinical studies exploring the treatment of secondarily infected dermatitis reveal that the efficacy of topical retapamulin is compar …
Erythromycin, retapamulin, pyridoxine, folic acid, and ivermectin inhibit cytopathic effect, papain-like protease, and M(PRO) enzymes of SARS-CoV-2.
Bello SO, Imam MU, Bello MB, Yunusa A, Ahmed Adamu A, Shuaibu A, Igumbor EU, Habib ZG, Popoola MA, Ochu CL, Yahaya Bello A, Deeni YY, Okoye I. Bello SO, et al. Front Cell Infect Microbiol. 2023 Nov 27;13:1273982. doi: 10.3389/fcimb.2023.1273982. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 38089816 Free PMC article.
To repurpose existing drugs for COVID-19, we previously showed, qualitatively, that erythromycin, retapamulin, pyridoxine, folic acid, and ivermectin inhibit SARS-COV-2-induced cytopathic effect (CPE) in Vero cells. AIM: This study aimed to quantitatively explore the inhib …
To repurpose existing drugs for COVID-19, we previously showed, qualitatively, that erythromycin, retapamulin, pyridoxine, folic acid …
148 results